United Therapeutics Corporation (UTHR) News
Follow United Therapeutics Corporation (UTHR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 42 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
FDA authorizes clinical trial of United Therapeutics’ Treprostinil-Iloprost SMI
The FDA authorized a clinical trial of United Therapeutics’ Treprostinil-Iloprost SMI.
REGULATION | Oct 28, 2026, 11:06 AM UTC
M
United Therapeutics Q3 Earnings Preview: Revenue Estimate at 781.14M USD
United Therapeutics is scheduled to report Q3'26 results on November 04 before the market opens. Revenue is estimated at 781.14 million USD and EPS at 6.01 USD.
EQUITY | Oct 28, 2026, 11:00 AM UTC
M
United Therapeutics authorizes additional $2 billion share repurchase
United Therapeutics Corporation announced an additional $2 billion share repurchase authorization.
EQUITY | Oct 22, 2026, 11:00 AM UTC
M
Liquidia Settles Six Patent Lawsuits With United Therapeutics
Liquidia settled six lawsuits with United Therapeutics, ending multiyear litigation over sales of its Yutrepia drug. Liquidia shares surged nearly 30% this morning.
EQUITY | Oct 14, 2026, 02:24 PM UTC
M
Liquidia Surges Nearly 37% After Settling United Therapeutics Litigation
Liquidia shares jumped nearly 37% in premarket trading after the drugmaker settled a years-long legal dispute with United Therapeutics over its lung disease drug. The settlement ends six lawsuits over patents, trade secr
EQUITY | Oct 14, 2026, 12:57 PM UTC
M
Liquidia Settles Lung Drug Dispute With United Therapeutics for $381 Million
The settlement ends six lawsuits over patents, trade secrets and contracts. Liquidia shares jumped nearly 40% in premarket trading Wednesday.
EQUITY | Oct 14, 2026, 11:50 AM UTC
M
United Therapeutics, Liquidia Settle Patent Litigation With $330.4M Payment
The settlement includes a $330.4 million aggregate payment to United Therapeutics and actions to remove the PH-ILD indication from Yutrepia’s label.
EQUITY | Oct 14, 2026, 11:13 AM UTC
M
FDA Accepts NDA Filings for UTHR
The headline also states that YUTREPIA is available and a $175 million payment was made, but provides no further details.
EQUITY | Oct 14, 2026, 07:05 AM UTC
M
Liquidia, United Therapeutics Settle Patent Dispute, Keeping Yutrepia on Market
Liquidia announced a global settlement with United Therapeutics, ending years of litigation and securing continued sales of its Yutrepia inhalation powder for pulmonary arterial hypertension.
EQUITY | Oct 13, 2026, 11:40 PM UTC
M
Liquidia to Pay $380.7 Million to Settle United Therapeutics Lawsuits
Liquidia said it reached an agreement with United Therapeutics that resolves all pending litigation between the companies. The $380.7 million will be paid in multiple installments this year and next.
EQUITY | Oct 13, 2026, 10:54 PM UTC
H
Liquidia Shares Plunge After Court Ruling Invalidates Yutrepia Patent
Liquidia (LQDA) shares fell sharply after a Delaware court ruled that its inhaled drug Yutrepia infringes on two claims of a United Therapeutics (UTHR) patent. The ruling follows a 57% drop in LQDA shares on Wednesday.
REGULATION | Oct 01, 2026, 06:08 PM UTC
H
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 200 points on Thursday. Shares of Progress Software Corp (NASDAQ: PRGS ) fell sharply in pre-market trading after the company reported third
LIVE | Oct 01, 2026, 12:01 PM UTC
M
United Therapeutics seeks FDA withdraw of Yutrepia approval
United Therapeutics believes it is entitled to an order instructing the FDA to withdraw the approval of Liquidia's new drug application for Yutrepia.
REGULATION | Sep 30, 2026, 11:23 PM UTC
M
United Therapeutics wins patent infringement ruling against Liquidia Technologies
The District Court for the District of Delaware ruled that Liquidia Technologies, Inc. infringes two claims of a patent held by United Therapeutics.
REGULATION | Sep 30, 2026, 11:23 PM UTC
H
Liquidia Shares Plunge After Court Rules Against Lung Drug Patent
Liquidia's shares dropped nearly 50% after a federal judge ruled that its lung drug infringes a key patent held by United Therapeutics, significantly impacting the drug's commercial prospects.
REGULATION | Sep 30, 2026, 07:46 PM UTC
L
Weekly Recap: CoughLess Trezmi NDA filing and ralinepag PDUFA
United Therapeutics Corporation (NASDAQ:UTHR) is advancing multiple pulmonary and transplant programs—filing an NDA this year for inhaled CoughLess Trezmi with launch planned next year, pursuing ralinepag and Tyvaso dry—
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Why United Therapeutics (UTHR) Shares Are Falling Today
What Happened? Shares of biotechnology company United Therapeutics NASDAQ:UTHRfell 4% in the afternoon session after Goldman Sachs initiated coverage of the stock with a Sell rating.Goldman Sachs analyst Andrea Newkirk b
EQUITY | Sep 24, 2026, 07:57 PM UTC
L
United Therapeutics Price Target Announced at $321.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 01:54 PM UTC
L
UTHR: Expanding into pulmonary fibrosis and COPD, targeting multi-billion revenue growth with new therapies
A major strategic shift is underway, expanding from orphan pulmonary hypertension to large pulmonary fibrosis and COPD markets, with multiple new products and formulations in late-stage development. Revenue is projected
NEWS | Sep 14, 2026, 10:23 PM UTC
L
UTHR: Transforming into a pulmonary fibrosis leader with blockbuster pipeline and $40B+ revenue ambitions
A major strategic shift is underway, expanding from pulmonary hypertension to pulmonary fibrosis and COPD, with multiple new products and formats targeting large, underserved patient populations. Strong clinical data, ro
NEWS | Sep 14, 2026, 09:40 PM UTC
L
UTHR: Pulmonary fibrosis breakthroughs and a robust pipeline drive a projected 10x revenue surge
A major clinical and commercial transformation is underway, with best-in-class pulmonary fibrosis data, a rapidly expanding pipeline, and a projected 10x increase in addressable market and revenue. Fourteen launches are
EQUITY | Sep 09, 2026, 10:35 PM UTC
M
United Therapeutics enters $477.6M accelerated share repurchase with Citi
United Therapeutics entered an accelerated share repurchase agreement with Citi to repurchase about $477.6 million of common stock under its existing buyback program. It will make an upfront payment around Sep 10, 2026.
EQUITY | Sep 08, 2026, 09:23 PM UTC
L
UTHR: Aggressive product launches and innovation aim for $50—100B revenue and industry leadership
Fourteen new products are set for rapid launch, targeting $50—100 billion in annual pharma revenue and addressing a million-patient market. Key innovations include once-daily and coughless inhalers, with strong IP protec
EQUITY | Sep 08, 2026, 04:40 PM UTC
M
UTHR to launch new pulmonary products; revenue target $50-100B
UTHR says new products aimed at pulmonary diseases are set to launch over the next few years, projecting $50–100 billion in annual revenue. Tyvaso and ralinepag are advancing through regulatory milestones.
EQUITY | Sep 08, 2026, 03:58 PM UTC
M
Roivant drug meets mid-stage goals; ROIV shares jump premarket
Roivant (ROIV) said its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
EQUITY | Sep 08, 2026, 10:59 AM UTC
L
United Therapeutics to present updates at four upcoming investor conferences
United Therapeutics Corporation said company executives will provide overviews and updates during fireside chat sessions at four upcoming investor conferences.
EQUITY | Sep 01, 2026, 11:00 AM UTC
H
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Con
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
GEOPOLITICS | Aug 28, 2026, 11:00 AM UTC
M
United Therapeutics says FDA accepts ralinepag NDA
United Therapeutics says the FDA accepted its new drug application for ralinepag to treat pulmonary arterial hypertension and set a PDUFA target action date of June 24, 2027.
REGULATION | Aug 24, 2026, 11:03 AM UTC
M
United Therapeutics FDA accepts ralinepag NDA, sets June 24, 2027 PDUFA
United Therapeutics says the FDA accepted its New Drug Application for ralinepag to treat pulmonary arterial hypertension and set a PDUFA date of June 24, 2027.
REGULATION | Aug 24, 2026, 11:03 AM UTC
L
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
EQUITY | Aug 20, 2026, 07:27 PM UTC
L
United Therapeutics Q2 Net Income $333m
United Therapeutics reports Q2 net income
EARNINGS | Aug 05, 2026, 10:36 AM UTC
L
QSR, UTHR, COLM, REXR, BYD, DUK, DTE near 200dma support
Seven stocks approach 200-day moving average support
EQUITY | Aug 03, 2026, 03:25 PM UTC
L
United Therapeutics Insider Sold Shares Worth $5,091,949, According to a Recent SEC Filing
() -- Martine A Rothblatt, Director, Chairperson & CEO, on July 13, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,091,949. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 66
REGULATION | Jul 14, 2026, 08:37 PM UTC
L
United Therapeutics Insider Sold Shares Worth $5,173,660, According to a Recent SEC Filing
() -- Martine A Rothblatt, Director, Chairperson & CEO, on July 10, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,173,660. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 66
REGULATION | Jul 13, 2026, 08:41 PM UTC
H
Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Frida
EARNINGS | Jul 10, 2026, 05:01 PM UTC
L
United Therapeutics Insider Sold Shares Worth $5,235,756, According to a Recent SEC Filing
() -- Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on July 09, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,235,756. Following the Form 4 filing with the SEC, Rothblatt has contro
REGULATION | Jul 10, 2026, 07:39 AM UTC
L
United Therapeutics Insider Sold Shares Worth $5,255,111, According to a Recent SEC Filing
() -- Martine A Rothblatt, Director, Chairperson & CEO, on July 08, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,255,111. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 66
REGULATION | Jul 09, 2026, 08:40 PM UTC
L
United Therapeutics Insider Sold Shares Worth $5,309,296, According to a Recent SEC Filing
() -- Martine A Rothblatt, Director, Chairperson & CEO, on July 07, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,309,296. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 66
REGULATION | Jul 08, 2026, 08:51 PM UTC
L
United Therapeutics Expands Immune Therapy Pipeline With Thymmune
United Therapeutics Corp. (NASDAQ: UTHR ) said Thursday it has acquired privately held Thymmune Therapeutics. Thymmune is a preclinical biotechnology company developing regenerative thymic cell therapies designed to rest
MNA | Jul 02, 2026, 01:06 PM UTC
L
United Therapeutics Acquired Thymmune Therapeutics For $140M In Cash
United Therapeutics Corporation (Nasdaq: UTHR ) announced today it has acquired Thymmune Therapeutics, Inc. ( Thymmune ), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic
EQUITY | Jul 02, 2026, 10:31 AM UTC
M
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
United Therapeutics Corporation (NASDAQ: UTHR ) said Monday that the U.S. Food and Drug Administration (FDA) has granted premarket approval for its LungFX device, marking a significant step in the company’s efforts to in
REGULATION | Jun 29, 2026, 04:50 PM UTC
M
The FDA Grants Premarket Approval To United Therapeutics' LungFX Device For Use In Centralized Ex Vivo Lung Perfusion, A Procedure That Enab
FDA grants premarket approval to United Therapeutics' LungFX device
REGULATION | Jun 29, 2026, 10:34 AM UTC